GeoVax Labs (GOVX): High Growth Stock Beats Earnings, Advances Mpox Vaccine and Cancer Therapy
GeoVax Labs Inc GOVX
$0.68
▼ -3.05%
($-0.02)
🎈 Low Float
🎢 High Beta
Open
$0.72
Prev Close
$0.70
Day Range
$0.68 – $0.74
52W Range
$0.64 – $20.00
Market Cap
$5.02M
Beta
3.74
EPS (TTM)
$-21.69
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1994-04-04 |
| Shares Out. | 7,370,000 |
| Website | geovax.com/ ↗ |
| Phone | 13026587581 |
| Employees | 19 |
| Net Income | -$4.4M |
| Free Cash Flow | -$18.4M |
| Total Assets | $4.6M |
| Total Liabilities | $2.9M |
| Equity | $1.8M |
About GeoVax Labs Inc
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
GeoVax Labs Inc is a publicly traded company under the ticker symbol GOVX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)